ACP
AVTX icon

Acuta Capital Partners’s Avalo Therapeutics AVTX Stock Holding History

Acuta Capital Partners’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.44M Buy
186,308
+125,500
+206% +$1.98M 2.4% 17
2026
Q1 		$908K Buy
+60,808
New +$951K 0.64% 24

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Acuta Capital Partners's AVTX Position: Q2 2026 in Review

Acuta Capital Partners increased its Avalo Therapeutics (AVTX) stake by 206% in Q2 2026, buying an estimated $1.98M and bringing the position to 186,308 shares worth $3.44M. The position accounts for 2.4% of the portfolio, ranked #17.

Acuta Capital Partners first reported a position in AVTX in Q1 2026 and has held it in 2 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Acuta Capital Partners held 186,308 shares of Avalo Therapeutics worth $3.44M as of Q2 2026.
  • Acuta Capital Partners bought 125,500 Avalo Therapeutics shares in Q2 2026, an estimated $1.98M.
  • Avalo Therapeutics made up 2.4% of Acuta Capital Partners's portfolio in Q2 2026, its #17 holding.
  • Acuta Capital Partners first reported a position in Avalo Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Acuta Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.